NCT02871791View on ClinicalTrials.gov

Palbociclib With Everolimus + Exemestane In BC

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

August 24, 2016

Primary Completion Date

December 3, 2020

Study Completion Date

September 30, 2021

Conditions
Human Epidermal Growth Factor 2 Negative Carcinoma of BreastHormone Receptor (HR)-Positive Breast Cancer
Interventions
DRUG

Palbociclib

DRUG

Everolimus

DRUG

Exemestane

Trial Locations (1)

02215

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT02871791 - Palbociclib With Everolimus + Exemestane In BC | Biotech Hunter | Biotech Hunter